BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rajabi M, Godugu K, Sudha T, Bharali DJ, Mousa SA. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α v β 3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme. Bioconjugate Chem 2019;30:3087-97. [DOI: 10.1021/acs.bioconjchem.9b00742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Ozen Karakus O, Godugu K, Mousa SA. Discovery of dual targeting PEGylated BG-P1600-TAT to norepinephrine transporter (NET) and thyrointegrin αvβ3 in the treatment of neuroblastoma. Bioorg Med Chem 2021;43:116278. [PMID: 34157571 DOI: 10.1016/j.bmc.2021.116278] [Reference Citation Analysis]
2 Kuo Y, Rajesh R. Particulate systems for improving therapeutic efficacy of pharmaceuticals against central nervous system-related diseases. Journal of the Taiwan Institute of Chemical Engineers 2020;114:12-23. [DOI: 10.1016/j.jtice.2020.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Glinsky GV, Godugu K, Sudha T, Rajabi M, Chittur SV, Hercbergs AA, Mousa SA, Davis PJ. Effects of Anticancer Agent P-bi-TAT on Gene Expression Link the Integrin Thyroid Hormone Receptor to Expression of Stemness and Energy Metabolism Genes in Cancer Cells. Metabolites 2022;12:325. [DOI: 10.3390/metabo12040325] [Reference Citation Analysis]
4 Karakus OO, Godugu K, Rajabi M, Mousa SA. Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma. J Med Chem 2020;63:7653-62. [DOI: 10.1021/acs.jmedchem.0c00537] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Mousa SA, Hercbergs A, Lin HY, Keating KA, Davis PJ. Actions of Thyroid Hormones on Thyroid Cancers. Front Endocrinol (Lausanne) 2021;12:691736. [PMID: 34234745 DOI: 10.3389/fendo.2021.691736] [Reference Citation Analysis]
6 Davis PJ, Mousa SA, Lin HY. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol Rev 2021;101:319-52. [PMID: 32584192 DOI: 10.1152/physrev.00038.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sudha T, Godugu K, Darwish NHE, Nazeer T, Mousa SA. Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management. Cancers (Basel) 2021;13:4070. [PMID: 34439224 DOI: 10.3390/cancers13164070] [Reference Citation Analysis]
8 Godugu K, Rajabi M, Mousa SA. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers (Basel) 2021;13:2780. [PMID: 34204997 DOI: 10.3390/cancers13112780] [Reference Citation Analysis]
9 Godugu K, Mousa SA, Glinsky GV, Lin H, Davis PJ. In Vivo Clearance of Apoptotic Debris From Tumor Xenografts Exposed to Chemically Modified Tetrac: Is There a Role for Thyroid Hormone Analogues in Efferocytosis? Front Endocrinol 2022;13:745327. [DOI: 10.3389/fendo.2022.745327] [Reference Citation Analysis]
10 Fujioka K, Godugu K, Mousa SA. Pharmacokinetics and biodistribution of a novel anticancer thyrointegrin αvβ3 antagonist: triazole modified tetraiodothyroacetic acid conjugated to polyethylene glycol (P-bi-TAT). AAPS Open 2021;7. [DOI: 10.1186/s41120-021-00036-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hay BA, Godugu K, Darwish NHE, Fujioka K, Sudha T, Karakus OO, Mousa SA. New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. J Med Chem 2021;64:6300-9. [PMID: 33886292 DOI: 10.1021/acs.jmedchem.1c00350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Schreiber CL, Zhai C, Smith BD. Structural Engineering of Fluorescent Self-Threaded Peptide Probes for Targeted Cell Imaging. Photochem Photobiol 2021. [PMID: 33934361 DOI: 10.1111/php.13439] [Reference Citation Analysis]
13 Yang W, Xuan B, Li X, Si H, Chen A. Therapeutic potential of 1,2,3-triazole hybrids for leukemia treatment. Arch Pharm (Weinheim) 2022;:e2200106. [PMID: 35532286 DOI: 10.1002/ardp.202200106] [Reference Citation Analysis]
14 Karakus OO, Godugu K, Fujioka K, Mousa SA. Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma. Bioorg Med Chem 2021;42:116250. [PMID: 34118788 DOI: 10.1016/j.bmc.2021.116250] [Reference Citation Analysis]
15 Sudha T, Godugu K, Glinsky GV, Mousa SA. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer. Biomedicines 2022;10:795. [DOI: 10.3390/biomedicines10040795] [Reference Citation Analysis]
16 Fallah Z, Isfahani HN, Tajbakhsh M, Mohseni M, Zabihi E, Abedian Z. Antibacterial and Cytotoxic Effects of Cyclodextrin-Triazole-Titanium Based Nanocomposite. Braz arch biol technol 2021;64:e21190750. [DOI: 10.1590/1678-4324-2021190750] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Abbas N, Yusuf M, Akhtar N, Khan RA. Contemporary nano-architectured drugs and leads for ανβ3 integrin-based chemotherapy: Rationale and retrospect. Nanotechnology Reviews 2022;11:204-19. [DOI: 10.1515/ntrev-2022-0020] [Reference Citation Analysis]